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Absorption and Distribution of Xenobiotics
by Frank G. Standaert*t
Extrapolation of pharmacokinetic data between species has been simplified by the advent of more
sensitive methods ofanalysis ofchemicals in body tissues and by the capability of inexpensive computers
to perform complex calculations. These new methods enable investigators to observe the rates at which
target tissues reachequilibrium indifferent species andtodevelopmathematical models ofthese processes.
The evaluation of physiological pharmacokinetics from classical or compartmental kinetics is improving
the ability to project the long-term behavior ofchemicals in body fluids and organs based on independently
derived physical, chemical, and physiological constants obtained from simple chemical reactions, tissue
culture experiments, or short-term animal studies. Accurate prediction of chemical behavior by such
models gives support to hypothetical mechanisms of distribution and accumulation, while significant
deviations from predicted behavior signal the existence of previously unsuspected pathways. These tech-
niques permit the simulation of the impact of linear, nonlinear, and saturation kinetics on chemical
behavior; the prediction of integrated tissue exposure; and the mapping of the sequence of alternate
metabolic pathways that lead to toxicity or detoxification. The discussion will identify the research needs
for improving extrapolations between species.
Introduction
Conventional long-term, high-dose in vivo assays
have a simple rationale: If there is something noxious
about a chemical, then repeatedly giving maximum
doses willmake the noxious effect appear among asmall
groupoftestanimals. Perhapssuchthinkingisadequate
to address the qualitative question of whether a com-
pound is noxious, but it has the serious drawback ofnot
addressingthe quantitative question ofhowmuch ofthe
compound is needed to bring forth the noxious effect.
Assays that use only two doses [i.e., the maximal tol-
erated dose (MTD) and one other] do not provide the
experimental insight into the shape and slope of the
dose-response curve that makes it possible to extrap-
olate from a high dose to a low dose. The problem is
even more perplexing when the task is to extrapolate
quantitatively across bothdosage regimens and species,
i.e., high doses in animals to low doses inhumanbeings.
Frequently the extrapolation is made by the simple
process of assuming that the same number of milli-
grams/kilograms/lifetime will produce equivalent re-
sults in animals and human beings. In reality, this ex-
trapolation cannot be done unless there are species
equivalence in responses and linear and/or known re-
lationships between the magnitude of the dose admin-
istered and the magnitude (or frequency) of the re-
sponse elicited.
Several papers in this symposium address the matter
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of whether there is a common mechanism of carcino-
genicity among species. This paper will address some
of the issues related to extrapolation from high doses
tolowdoses. Whentheshapeofthedose-response curve
is not known, the problems of extrapolating between
doses become very difficult (1-3). Under these circum-
stances, the relationship between the dose ofachemical
administered to an animal and the concentration ofthat
chemical atits site ofaction becomes the focus ofstudy.
The dose-response curve is traditionally used forpre-
dicting the relationship between the administered dose
and the response; however, the fact that the concen-
tration of the chemical at its site of action and/or the
time for which that concentration is maintained is more
relevant than the dose that was administered is fre-
quently overlooked. This discussion will focus on some
of the factors that influence the relationship between
the dose administered and the concentration reached
and maintained at the site of action.
With the understanding that current knowledge of
various aspects ofdose extrapolation is deficient, a sys-
tem will be reviewed by which extrapolation from one
species to another and one dose to another may be at-
tempted. However, it should be appreciated from the
outset that this form of extrapolation is in its infancy
and that many of the needed data or extrapolation pa-
rameters are not available at this time. While the lim-
itations ofknowledge cause large error factors to enter
the calculations, even currently available information
can produce results that are more accurate and more
scientific than other systems currently used. The esti-
mates will improve as knowledge ofthe basic biological
processes governing carcinogenicity and pharmacoki-
netics becomes available.F. G. STANDAERT
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FIGURE 1. Determinants of concentration. Modified from Green-
blatt and Shader (17).
Extrapolation When Pharmacokinetic
Factors Are Linear
To make the extrapolation from administered dose to
the concentration invivo, itis necessary to considerthe
absorption, distribution, and elimination of the com-
pound at the doses administered to the species in ques-
tion. Concentration is defined as quantity/volume (Fig.
1). For in vivo studies, the quantity ofthe chemical in
the bodyisthe difference betweenthe amount absorbed
and the amount eliminated. Because the chemical is
eliminated continuously, the concentration may vary
widelyifthe chemical is given inpulses (e.g., in a single
dailydose). Abetterunderstandingoftheinstantaneous
value of the concentration may be determined by con-
sidering the rate of absorption and the rate of elimi-
nation.
Volume is directly related to animal size. In phar-
macokinetic studies, it is important to understand that
the volume of the study animal provides information
about the amount of potential solvents (e.g., water,
lipid, protein) that is available in the animal's body to
concentrate xenobiotics and the manner in which the
chemistryofaparticularxenobioticwilldictatepartition
among those solvents (4).
For orally administered xenobiotics, there are many
factors that may influence the absorption and the be-
havior of a particular compound at a specific time (5-
11). These include anatomy, age, and pKa of the com-
pound, pH ofthe gut, diet, and gutflora. There are two
major factors that dominate the consideration of xe-
nobiotics absorption in study animals (12-16). First,
nearly all xenobiotics cross the GI tract from the gut
lumen to the blood by simple diffusion. The rate ofdif-
fusionis controlled bythe concentrationgradientacross
the GI wall. Second, the major barrier to diffusion is
the GI wall. The wall behaves as if it were a sheet of
lipid separating water phases on one side (i.e., the GI
lumen) from those on the other (i.e., the blood). It fol-
lows that in order to be absorbed predictably, a xeno-
biotic must be water soluble to be dissolved in the GI
lumenandbecarried awaybytheblood andlipidsoluble
so it can diffuse across the GI wall.
Many compounds do not have the blend of lipid and
water solubilities to enable their efficient absorption.
However, those xenobiotics that demonstrate these
unique qualities may be presumed to be absorbable by
all species, unless the experiment is modified by such
external factors as the vehicle used, diet, debilitation,
diarrhea, or bacterial degradation. These modifications
can be understood before the experiment or observed
during study to permit appropriate corrections by the
investigator. Once the xenobiotic crosses the gut wall,
it enters the gastrointestinaltissues andthentheportal
vein. From there it courses through the liver and into
the systemic circulation (Fig. 2). The xenobiotic is dis-
tributed by the blood to all tissues, includingthe target
tissue containing the site of action.
Ifthere is no species-specific or rate-limiting process
involved in the absorption of the xenobiotic into the
blood and passage through the presystemic circulation
::: Portal Liver
To Site of
Measure-
kK.:K.Y ~~~~~ment
Metabolism
FIGURE 2. Pathways followed by xenobiotics administered orally. Modified from Gibaldi (13).
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FIGURE 3. Illustration ofthe affect on apparent volume ofdistribution ofsolubility in body constituents. Left: the major chemical constituents
in the body; center: apparent volume of distribution ofcompounds soluble only in water; right: apparent volume distribution ofcompounds
soluble in water, fat, and protein. Q; quantity of xenobiotic administered IV; [ ]PH2O concentration of xenobiotic in plasma water at
equilibrium; Vd, apparent volume of distribution.
(i.e., gastrointestinal tissues, portal blood, and liver),
the agent is distributed to and among the organs. The
rate of distribution and the ultimate concentration of
the chemical in the organs vary between species, but
the factors governing these parameters are understood
and can provide a means for extrapolating from one
species to another.
The use of pharmacokinetic methods to extrapolate
between species is based upon knowledge ofthe rate at
which the chemical is delivered to the various tissues
and the ultimate concentration attained in each of the
various tissues. The rate at which a chemical is deliv-
ered to an organ depends upon the rate at which the
blood containing the chemical is delivered to the organ.
Information on the rate of blood flow to organs of lab-
oratory animals is available in the literature (18-23).
Therate ofdeliveryofachemicalto anyparticular organ
can be predicted from information on the rate of blood
flow. Similarly, inthe absence ofdestruction ofthe com-
pound in the organ (i.e., metabolism), the compound is
removed by blood, and so the rate of elimination may
also be calculated.
When the rate ofdelivery and the rate ofelimination
are in balance, the system is in equilibrium, and the
quantity ofthe chemical in an organ is purely a function
of the solubility of the chemical in the solvents in that
organ. This is referred to as a partitioning ofthe chem-
ical among the various potential solvents and can be
estimated from data obtained in vitro (4,16).
The preferential concentration of a chemical in one
tissueratherthananotherleadsto anapparent variation
in the volume of distribution of chemicals, and so can
affect the calculation of concentration (24,25). For ex-
ample, if the concentration of the chemical in blood
water is to be calculated, it will not be dependent upon
the real volume or size of the animal, but it will be
dependent ontheapparentvolumeinwhichthechemical
is distributed (i.e., the volume of the available water-
soluble partition). The apparent volume will be much
smaller for a chemical that is highly soluble in water
and poorly soluble in lipid than for a chemical that has
the opposite set of characteristics (Fig. 3). Since the
apparent volume of the water-soluble chemical is
smaller than that ofthe lipid-soluble chemical, the con-
centration in water will be much greater for the former
than for the latter, even if the same amounts of these
two chemicals enter the body.
The rate ofdelivery, the rate ofelimination, and the
apparent volume of the solvent partition can be deter-
mined for any particular chemical given to a laboratory
animal. Furthermore, procedures are available for ex-
trapolatingthe values from one species to anotherusing
mathematical methods of scaling between species. The
characteristics of available mathematical methods for
scaling have been discussed by several investigators
(18,19,21,26-30). Allometry is among the more widely
used procedures currently used for scaling dose be-
tween species. This procedure evaluates the way in
which various physiologic parameters are related to the
weight of the animal according to the general formula
y = aWb in which y is the value of the parameter in
one species, W is the weight of the species, and a and
b are empirically determined interspecies scaling fac-
tors. Bytakingthelogarithmofbothsides, thisequation
may be rearranged to log y = log a + b log W.
This approach permits estimation of important ana-
tomic or physiologic parameters that affect chemical
absorption, distribution, or clearance (31,32). By ap-
propriate use of these factors, corrections may also be
made for differences in the lifetimes ofthe animals and
estimates of various rate functions may be derived
(18,19,26,29).
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Scaling measures allow normalization of various pa-
rameters among species, but deal with the parameters
on an item-by-item basis (e.g., volume of distribution,
liver weight, time) and are not by themselves capable
ofproviding a model ofa whole body or ofthe dynamic
status ofa xenobiotic (Figs. 4-7). This approach can be
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FIGURE 6. Relationshipofplasmaconcentration as afunctionoftime
in two species, uncorrected. AUC, area under curve. Modified
from Boxenbaum (18).
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FIGURE 4. Apparent volume ofdistribution offourxenobioticswhen
appropriate scaling factors are used (29).
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FIGURE 5. Liverweight (left scale and upperline) and hepatic blood
flow (right scale and lower line) as a function of body weight in
various species. Modified from Boxenbaum (26).
combined with modeling via physiological pharmacoki-
netics to provide a better picture of scaling (23,33-35).
Physiological pharmacokinetic models differ from the
more familiar compartmental pharmacokinetic models
in that they are constructed from an array of known
physiological and chemical parameters that enable pre-
diction ofchemical behavior prior to the experiment. In
contrast, compartmental kinetics begin with experi-
mental dataand seekto construct amathematical model
of the body that fits the observed data. Physiological
models becomeincreasingly accurate asadditionalphys-
iological factors are incorporated into the model. How-
ever, withthe additionofeachphysiological component,
the mathematics become increasingly complex and com-
puters are needed to solve the numerous differential
equations. An example of a physiologic model for use
in pharmacokinetics is shown in Figure 6. The appli-
cationofaninterspecies scalingfactortoeachparameter
adds to the mathematical complexity, but allows the
model to be extrapolated from one species to another.
An example ofthe data used for interspecies scaling of
thephysiological model ofFigure 8 ispresented in Table
Interspecies extrapolation by this method is a re-
cently developed approach that is still evolving. The
approach has several limitations. For example, the in-
formation presented in Figure 5 is plotted on a log-log
scale to make the scattered deviation of data around
these lines appearsmallerthanitwould in anonlogscale
plot of this information. Nonetheless, the method has
been used to predict the pharmacokinetic behavior of
several drugs (23,31,36,37). This approach could be
adapted to estimate the dose extrapolations involved in
carcinogenicity assays.
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FIGURE 7. Relationship of plasma concentration as a function of time in two species, corrected by factors that accommodate for differences
in life span of the two species. Line at bottom contains general scaling factors that may be used to approximately normalize time scales
among species. Cl, clearance; V, volume; AUC, area under curve; B, body mass, kilograms. Modified from Boxenbaum (18).
Table 1. Physiological parameters for modeling in the 0.25-kg
rat and the 70-kg man.a
Volume, mL Blood flow rate, mL/min
Compartment Rat Human Rat Human
Brain 1.2 1,500 1.1 760
Lung 1.2 1,200 44.5 6,330
Heart 1.0 300 4.2 240
Liver 11.0 1,500 14.7 1,580
Kidney 2.0 300 11.4 1,240
GI tract 11.1 2,400 12.0 1,200
Muscle 125.0 30,000 6.8 300
Skin 43.8 7,800 4.5 1,950
Adipose tissue 10.0 12,200 1.8 260
Blood
Artery 6.8 1,800
Vein 13.6 3,600
aModified from Igari et al. (23).
Extrapolation When
Pharmacokinetic Factors Are
Nonlinear
Extrapolation by the approach described is based on
a premise that does not apply to the usual carcinogen-
icity assay conditions. This is because many of the ki-
netic parameters used in the model are not known, and
these parameters cannot always be normalized across
doses or species using mathematical methods. One rea-
son that the proposed method cannot be currently ap-
plied is that the extrapolation procedures presuppose
thatchangesinchemicalconcentration followfirst-order
kinetics in all species and at all concentrations (i.e., that
the fraction ofchemical absorbed or eliminated per unit
time is constant and independent of concentration). If
this condition is not met, then the pharmacologic phe-
nomena being scaled are not linear and it is usually not
possible to predict from knowledge ofone circumstance
what is likely to happen at another. The analytic ap-
proach requires that most processes, particularly the
elimination processes, follow first-order kinetics. Car-
cinogenicity assays, however, are conducted with very
high doses of the xenobiotic that almost certainly sat-
urate the eliminating process so that clearance follows
zero-order kinetics. If this latter case prevails, then it
may not be possible to extrapolate from knowledge of
the dose administered to the item that must be known
(i.e., the concentration of the chemical at its site of
action).
Zero-order kinetics describe a process in which the
elimination of a compound occurs at a constant rate,
regardless of concentration. This is expressed mathe-
matically by the equation -dcldt = k. First-order ki-
netics describes a process in which the elimination ofa
compound is proportional to the concentration, -dcldt
= kc (12,13,17,38-40). The differences in the processes
are shown graphically in Figure 9.
This difference is seen in organs ofelimination (e.g.,
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A. Regular Plot
FIGURE 8. Diagram of a physiologically based pharmacokinetic
model used to predict drug distribution. Organs are represented
as compartments perfused by the vascular system. Q, quantity of
chemical. Modified from Igari et al. (23).
liver). All chemicals entering the body via the GI tract
must go through the presystemic circulation (38) where
they are subject to destruction by enzymes in the in-
testine and/or liver (Fig. 2). This destruction is an ac-
tive, enzyme-mediated process, which, although very
efficient, can also be limited in capacity and may be
easily overloaded. The enzymes are limited in both the
rate at which individual molecules can catalyze a reac-
tion and in the number ofenzyme molecules present in
the tissue. As a result, the liver may metabolize only a
specific number of molecules per second. If additional
molecules ofxenobiotic are present in the portal blood,
they pass through a system in which the destructive
processes are fully saturated, thereby gaining entry to
other compartments ofthe body unchanged.
The basic characteristics of an enzyme system are
specified inthe Michaelis-Menten formula, which canbe
expressed mathematically as follows:
V = Vm.
- ClKm + C
This relationship requires that V (the velocity with
which a xenobiotic is metabolized) increases linearly
only when C (the concentration ofthe substrate for the
enzyme) is very small compared to the capacity of the
enzymatic system. As Cincreases, velocity increases as
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FIGURE 9. Zero-order and first-order elimination kineticsplottedon
arithmetic (A) and semilogarithmic (B) scales (40).
a nonlinear function until the reaction becomes satu-
rated and V becomes a constant that does not change
with further increases in C (6,13,39). A graphic rep-
resentation of the relationship between V and C is
shown in Figure 10.
This relationship between rate ofmetabolism and en-
zyme substrate concentration is important because it
explains that the whole system changes when the con-
centration ofthe xenobiotic is sufficient to saturate the
elimination enzymes. Under these conditions the kinet-
ics of the changed system become complex, and there
is no easy way of predicting what will happen to the
compound or to the test animal (6,41,42).
For example, the xenobiotic may accumulate in the
organismwithoutlimitwhentheeliminationmechanism
is saturated. Without ameans forthe organismto elim-
inate the excess material, it stays in the body, increas-
ingin concentrationwith each additional dose (Fig. 11).
The chemical may have toxic effects not seen at lower
concentrations because the concentration may rise to
extraordinary levels.
A variety ofnonspecific effects may be caused by the
amount of chemical in the body. If nothing stops the
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rise in concentration, the animal will die; however,
sometimes secondary metabolic pathways are invoked
atthehighconcentration. Thesemaylimittheincreased
body burden ofchemical, butthey may also initiate new
mechanisms of toxicity, particularly if a metabolite is
toxic (3).
Saturation of metabolizing enzymes can have differ-
ent effects on toxicity, depending upon whether the
parentmolecule oritsmetaboliteisthetoxicagent(Fig.
12). If toxicity is due to the parent molecule, toxicity
can increase as concentration rises, because more par-
ent molecules escape destruction and become available
systemicallyasthemetabolizingenzymesaresaturated.
Onthe otherhand, iftoxicityis dueonlyto ametabolite,
then toxicity reaches a plateau and will not increase
with dose after a saturating concentration is attained,
because the organism cannot increase the amount of
metabolite it makes regardless of how much chemical
becomes available.
Saturation of elimination pathways can bring forth
toxicity not usually seen. For example, this can occur
if the compound is usually destroyed before it leaves
the liver. In this case, saturation of liver enzymes will
cause some of the parent molecules to spill into the
systemic circulation and initiate effects that would not
be seen in more moderate circumstances (Fig. 13). In
this situation a major difference in toxicity may be ob-
served in animals given a xenobiotic by gavage and
those given an identical dose in the water or diet.
Administration of the chemical by gavage delivers a
highpulselike concentrationintheportalbloodthatmay
exceed the concentration needed to saturate liver en-
zymes. In this case, the parent chemical will spill into
the systemic circulation. A chemicaladministered inthe
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FIGURE 11. Effect on concentration of material in the body when
the rate of absorption is less than, approximately equal to, and
greater than Vm_,, ofthe eliminating enzymes. LinesA, B, and C:
compound administered at rate of 1500, 1000, and 100 mg/kg/day,
respectively. Vmax is 1100 mg/kg/day (6).
FIGURE 12. Relationships between administered dose and toxic ma-
terial in body. Center line depicts situation in which parent mole-
cule is the toxic material and clearance is not saturated. Upper
line depicts situation in which the toxic agent is a metabolite of
the parent molecule and the enzymes are saturable. Bottom line
depicts situation in which the parent molecule is the toxic material
and the clearing enzymes are saturable (3).
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FIGURE 13. Relationship between administered dose and amount of
toxic material in systemic circulation in a situation in which small
doses oforally administered material are cleared by the liver but
larger doses saturate the clearing process (44).
diet, however, tends to be ingested over a period of
many hours (43), and the resulting concentration in the
portal blood may never reach enzyme saturation levels.
Summary
Onthetheoretical basis describedinthispresentation
and elsewhere, it is easy to understand why there is so
much concern about the scientific accuracy with which
we extrapolate from animal carcinogenicity assays to
the human situation. The base ofknowledge necessary
to make the extrapolation is currently incomplete. This
is because on a qualitative basis, there is uncertainty
about the mechanisms ofcarcinogenesis, and on a quan-
titative basis, there are inadequate data to extrapolate
from dose to dose.
For the long term, there is a need to continue study
of the mechanisms of carcinogenesis. In the context of
this presentation, the most important factors that must
be known are the relationship between the concentra-
tion of the agent at its site of action and the response
of the biologic system to that concentration. There is
alsoaneedtoknowtheshapeofthedose-response curve
forthe carcinogenic agent andwhetherthecarcinogenic
agent is the parent molecule or one or more of its me-
tabolites. Until these facts are known, the ability to
extrapolate knowledgeably from test situations in lab-
oratory animals to humans willbe limited because there
is no understanding of what is being extrapolated to
where.
While awaiting the results of the studies that will
provide the needed knowledge, present methods can be
improved by applying available information about car-
cinogenesis and pharmacokinetics. There is a need to
expand quantitative research programs. Preliminary
studies ofcompounds to be tested in chronic assays can
be enhanced to permit a better understanding about
physiochemical processes and to enable prediction of
distribution patterns. Absorption can also be studied
under the conditions of the assay, or if necessary, the
assay can be redesigned to take account of absorption.
Themetabolismoftheagentcanbestudiedtodetermine
whether or not the clearing processes will become sat-
urated by the proposed doses of the agent and what
this will mean in the interpretation ofthe assay results.
Much of this needed information can be provided by
existingtechnology. Forexample, samplingofbloodwill
provide information about the pharmacokinetics of ab-
sorption, clearance, and accumulation of the chemical.
The study ofa wider range ofdoses than current prac-
tice could give information about the shape ofthe dose-
response curve and may indicate whether or not an
active metabolite is involved in the toxicity. Consider-
ation of the known physiological and biochemical dif-
ferences among species will improve understanding of
interspecies projections.
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